Study: NCT04620109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KDR2-2
Description: KDR2-2 is a synthetic anti-angiogenic chemical compound with highly effective inhibition on vascular endothelial growth factor receptor-2 (VEGFR2), and an additional, moderate inhibitory effect on platelet-derived growth factor receptor β (PDGFRβ).~KDR2-2 suspension eye drop is in development for the treatment of corneal neovascularization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo : the formulation and the product process of placebo are the same as the KDR2-2 eye drops, but without API .